Presentation tomorrow NEW YORK, Aug. 14, 2019 (
Post# of 153822
(Total Views: 679)
Posted On: 08/14/2019 10:14:07 AM
Presentation tomorrow
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter will be hosting the “Next Super Stock - Live!” livestream online-only investor conference on Thursday August 15, 2019 from 12:00PM-1:00PM EST. Registration is free. Click here to join: https://www.wallstreetreporter.com/next-super...ivestream/
12:40PM EST - CytoDyn Inc. (CYDY) Nader Pourhassan, Ph.D, CEO.
CEO Dr. Nader Pourhassan will update investors on the latest developments for CytoDyn’s lead drug candidate, Leronlimab (PRO 140) for use as a Combination Therapy to treat HIV, and expecting FDA approval in early 2020. Dr. Pourhassan will also share what’s ahead for the company’s pipeline for cancer indications.
Expected FDA approval for Leronlimab (PRO 140) for use as a Combination Therapy to treat HIV, offers multi-billion dollar near-term revenue potential.
Lending validation to the opportunity, Samsung Biologics is manufacturing significant amount of Leronlimab with payments deferred to mostly post-FDA approval.
Leronlimab (PRO 14) drug development pipeline for: Melanoma, Pancreatic, Prostate, Lung, Liver and Stomach Cancer - NASH - GvHD
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Wall Street Reporter will be hosting the “Next Super Stock - Live!” livestream online-only investor conference on Thursday August 15, 2019 from 12:00PM-1:00PM EST. Registration is free. Click here to join: https://www.wallstreetreporter.com/next-super...ivestream/
12:40PM EST - CytoDyn Inc. (CYDY) Nader Pourhassan, Ph.D, CEO.
CEO Dr. Nader Pourhassan will update investors on the latest developments for CytoDyn’s lead drug candidate, Leronlimab (PRO 140) for use as a Combination Therapy to treat HIV, and expecting FDA approval in early 2020. Dr. Pourhassan will also share what’s ahead for the company’s pipeline for cancer indications.
Expected FDA approval for Leronlimab (PRO 140) for use as a Combination Therapy to treat HIV, offers multi-billion dollar near-term revenue potential.
Lending validation to the opportunity, Samsung Biologics is manufacturing significant amount of Leronlimab with payments deferred to mostly post-FDA approval.
Leronlimab (PRO 14) drug development pipeline for: Melanoma, Pancreatic, Prostate, Lung, Liver and Stomach Cancer - NASH - GvHD
(4)
(0)